Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 361 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tumor markers Clear all

Conditions: Breast Cancer
Interventions: Physical Evaluation, Dual-energy X-ray absorptiometry scans, Trabecular Bone Score; Other · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Metastatic Breast Cancer
Interventions: Genomic and Proteomic Profiling; Other
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions: Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Hysterectomy, Laboratory Biomarker Analysis, Lymph Node Mapping, Sentinel Lymph Node Biopsy; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer, Urothelial Carcinoma Bladder
Interventions: Not listed
Lead sponsor: Pangea Laboratory LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Melanoma
Interventions: tvs-CTL Vaccine; Biological
Lead sponsor: Gary Doolittle; Other
Eligibility: 18 Years to 66 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Fairway, Kansas

Conditions: Melanoma
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Murray, Utah • Salt Lake City, Utah

Conditions: Smoking Cessation
Interventions: Vignette, questionnaires and Saliva Samples, Urine Collection, Smoking cessation treatment; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: GSK2118436, Midazolam; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York • Nashville, Tennessee + 1 more

Conditions: Colorectal Cancer
Interventions: Vitamin D intervention, Placebo intervention; Dietary Supplement
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Precancerous Condition
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2045
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
Interventions: Multi-analyte Blood Test; Diagnostic Test
Lead sponsor: Helio Genomics; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Timeline: 2019 – 2028
U.S. locations: 7
States / cities: Redondo Beach, California • Coon Rapids, Minnesota • Fridley, Minnesota + 4 more

Conditions: Advanced Cancers
Interventions: Biomarker Research; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer, Non-small Cell Lung Cancer
Interventions: PET/CT and BH PET/CT; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Prostate Cancer
Interventions: Bariatric Surgery; Other
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 20 Years to 60 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Malignant Testicular Germ Cell Tumor
Interventions: Clinical Stage I Disease, Clinical Stage I with relapse, CSII Disease; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Male only
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 2 more

Conditions: Stroke, Cancer
Interventions: Blood tests, Transcranial Doppler Microemboli Detection Study; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: New York, New York

Conditions: Advanced Cancers
Interventions: Treatment Based on Genetic Mutation, Treatment Based on No Genetic Mutation; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatoblastoma, Hepatocellular Carcinoma, Rhabdoid Tumor of Liver, Undifferentiated (Embryonal) Sarcoma of the Liver, Pediatric Liver Cancer, Liver Tumors
Interventions: Quality of Life Assessment, Transarterial Radioembolization; Behavioral · Radiation
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 0 Years to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Wilmington, Delaware • Jacksonville, Florida

Conditions: HIV Infections
Interventions: Tumor Necrosis Factor soluble receptor-immunoadhesin complex; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 3
States / cities: Honolulu, Hawaii • New York, New York • Cleveland, Ohio

Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Interventions: OR2805, Cemiplimab, Docetaxel; Drug
Lead sponsor: OncoResponse, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Austin, Texas • San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood, Biomarkers, Immunotherapy
Interventions: Carboplatin/Cisplatin -Etoposide - Atezolizumab; Drug
Lead sponsor: Oncology Center of Biochemical Education And Research; Other
Eligibility: 18 Years to 85 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: DNA stability analysis, loss of heterozygosity analysis, microsatellite instability analysis; Genetic
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Barrett's Esophagus
Interventions: response to therapy; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Search by objective public record fields.

Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors

Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer

Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases

Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma

Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

Biomarkers of Molecular Risk in Smokers

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

Vitamin D Intervention and Associated Changes in the Gut Microbiome and Vitamin D Levels in Healthy Adults

Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients

Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis

Effect of Lap-Band Induced Weight Loss on Serum PSA Levels

MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial

Mechanisms of Ischemic Stroke in Cancer Patients

Rational Therapeutics Based on Matched Tumor and Normal Tissue

Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors

A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Blood Markers of Early Pancreas Cancer

Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)

Genetic Markers in Patients With Colorectal Cancer

Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation